Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: Suppression of Spry4 enhances cancer stem cell properties of human MDA-MB-231 breast carcinoma cells

Authors: Hongyu Jing, Lucy Liaw, Robert Friesel, Calvin Vary, Shucheng Hua, Xuehui Yang

Published in: Cancer Cell International | Issue 1/2017

Login to get access

Excerpt

Upon publication of the original article [1], it was noted that the Core Facilities utilized by the authors for their research were not adequately acknowledged in the manuscript. In this case, the following was mistakenly omitted:
  • Progenitor cell analysis core
  • Molecular Phenotyping core
  • Stem Cell COBRE Grant P30GM106391
  • Vascular Biology COBRE Grant P30GM103392
…
Literature
1.
Metadata
Title
Erratum to: Suppression of Spry4 enhances cancer stem cell properties of human MDA-MB-231 breast carcinoma cells
Authors
Hongyu Jing
Lucy Liaw
Robert Friesel
Calvin Vary
Shucheng Hua
Xuehui Yang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2017
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-017-0423-9

Other articles of this Issue 1/2017

Cancer Cell International 1/2017 Go to the issue

Primary research

Human U87 glioblastoma cells with stemness features display enhanced sensitivity to natural killer cell cytotoxicity through altered expression of NKG2D ligand

Review

Biomechanical cell regulatory networks as complex adaptive systems in relation to cancer

Primary Research

MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma

Primary Research

pATM and γH2AX are effective radiation biomarkers in assessing the radiosensitivity of 12C6+ in human tumor cells

Primary Research

Down-regulation of IFITM1 and its growth inhibitory role in cervical squamous cell carcinoma

Primary Research

The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits